123 related articles for article (PubMed ID: 16314154)
1. The prolonged half-lives of new erythropoietin derivatives via peptide addition.
Lee DE; Son W; Ha BJ; Oh MS; Yoo OJ
Biochem Biophys Res Commun; 2006 Jan; 339(1):380-5. PubMed ID: 16314154
[TBL] [Abstract][Full Text] [Related]
2. Development of a long-acting erythropoietin by fusing the carboxyl-terminal peptide of human chorionic gonadotropin beta-subunit to the coding sequence of human erythropoietin.
Fares F; Ganem S; Hajouj T; Agai E
Endocrinology; 2007 Oct; 148(10):5081-7. PubMed ID: 17641000
[TBL] [Abstract][Full Text] [Related]
3. Production and characterization of long-acting recombinant human albumin-EPO fusion protein expressed in CHO cell.
Joung CH; Shin JY; Koo JK; Lim JJ; Wang JS; Lee SJ; Tan HK; Kim SL; Lim SM
Protein Expr Purif; 2009 Dec; 68(2):137-45. PubMed ID: 19595770
[TBL] [Abstract][Full Text] [Related]
4. Recombinant thyrotropin containing a beta-subunit chimera with the human chorionic gonadotropin-beta carboxy-terminus is biologically active, with a prolonged plasma half-life: role of carbohydrate in bioactivity and metabolic clearance.
Joshi L; Murata Y; Wondisford FE; Szkudlinski MW; Desai R; Weintraub BD
Endocrinology; 1995 Sep; 136(9):3839-48. PubMed ID: 7544273
[TBL] [Abstract][Full Text] [Related]
5. [Expression of rhEPO-L-Fc fusion protein and analysis of its bioactivity and pharmacokinetics].
Zhu Q; Huang Z; Huang Y; Qin Y
Sheng Wu Gong Cheng Xue Bao; 2008 Nov; 24(11):1874-9. PubMed ID: 19256332
[TBL] [Abstract][Full Text] [Related]
6. 3'-Half of the thrombopoietin cDNA confers higher expression of erythropoietin at the RNA level but not at the protein level.
Kim TW; Ji JW; Chang HG; Kim MO; Ryoo ZY; Park IK; Kim SJ
Mol Cells; 2005 Apr; 19(2):198-204. PubMed ID: 15879702
[TBL] [Abstract][Full Text] [Related]
7. Efficient preparation and PEGylation of recombinant human non-glycosylated erythropoietin expressed as inclusion body in E. coli.
Wang YJ; Liu YD; Chen J; Hao SJ; Hu T; Ma GH; Su ZG
Int J Pharm; 2010 Feb; 386(1-2):156-64. PubMed ID: 19932158
[TBL] [Abstract][Full Text] [Related]
8. [Eukaryotic expression, purification and analysis of the fusion protein of Epo-Tpo(C)].
Wang Z; Hou Y; Yang X
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2001 Mar; 15(1):5-8. PubMed ID: 12526292
[TBL] [Abstract][Full Text] [Related]
9. Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis.
Savino C; Pedotti R; Baggi F; Ubiali F; Gallo B; Nava S; Bigini P; Barbera S; Fumagalli E; Mennini T; Vezzani A; Rizzi M; Coleman T; Cerami A; Brines M; Ghezzi P; Bianchi R
J Neuroimmunol; 2006 Mar; 172(1-2):27-37. PubMed ID: 16337691
[TBL] [Abstract][Full Text] [Related]
10. PEGylation markedly enhances the in vivo potency of recombinant human non-glycosylated erythropoietin: a comparison with glycosylated erythropoietin.
Wang YJ; Hao SJ; Liu YD; Hu T; Zhang GF; Zhang X; Qi QS; Ma GH; Su ZG
J Control Release; 2010 Aug; 145(3):306-13. PubMed ID: 20427020
[TBL] [Abstract][Full Text] [Related]
11. Development and characterization of novel erythropoiesis stimulating protein (NESP).
Egrie JC; Browne JK
Br J Cancer; 2001 Apr; 84 Suppl 1(Suppl 1):3-10. PubMed ID: 11308268
[TBL] [Abstract][Full Text] [Related]
12. A new strategy for metabolic stabilization of motilin using the C-terminal part of ghrelin.
Morozumi N; Sato S; Yoshida S; Yamaki A; Furuya M; Inomata N; Ohnuma N; Minamitake Y; Ohsuye K; Kangawa K
Peptides; 2012 Feb; 33(2):279-84. PubMed ID: 22286034
[TBL] [Abstract][Full Text] [Related]
13. Improvement of Fc-erythropoietin structure and pharmacokinetics by modification at a disulfide bond.
Way JC; Lauder S; Brunkhorst B; Kong SM; Qi A; Webster G; Campbell I; McKenzie S; Lan Y; Marelli B; Nguyen LA; Degon S; Lo KM; Gillies SD
Protein Eng Des Sel; 2005 Mar; 18(3):111-8. PubMed ID: 15820978
[TBL] [Abstract][Full Text] [Related]
14. Novel erythropoiesis stimulating protein.
Macdougall IC
Semin Nephrol; 2000 Jul; 20(4):375-81. PubMed ID: 10928340
[TBL] [Abstract][Full Text] [Related]
15. Plant recombinant erythropoietin attenuates inflammatory kidney cell injury.
Conley AJ; Mohib K; Jevnikar AM; Brandle JE
Plant Biotechnol J; 2009 Feb; 7(2):183-99. PubMed ID: 19055608
[TBL] [Abstract][Full Text] [Related]
16. Effects of ammonia and glucosamine on the heterogeneity of erythropoietin glycoforms.
Yang M; Butler M
Biotechnol Prog; 2002; 18(1):129-38. PubMed ID: 11822911
[TBL] [Abstract][Full Text] [Related]
17. Immunological response to repeated administration of recombinant human erythropoietin in rats: biphasic effect on its pharmacokinetics.
Kato M; Miura K; Kamiyama H; Okazaki A; Kumaki K; Kato Y; Sugiyama Y
Drug Metab Dispos; 1997 Sep; 25(9):1039-44. PubMed ID: 9311618
[TBL] [Abstract][Full Text] [Related]
18. High-dose erythropoietin alters platelet reactivity and bleeding time in rodents in contrast to the neuroprotective variant carbamyl-erythropoietin (CEPO).
Kirkeby A; Torup L; Bochsen L; Kjalke M; Abel K; Theilgaard-Monch K; Johansson PI; Bjørn SE; Gerwien J; Leist M
Thromb Haemost; 2008 Apr; 99(4):720-8. PubMed ID: 18392330
[TBL] [Abstract][Full Text] [Related]
19. Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency.
Fauser BC; Mannaerts BM; Devroey P; Leader A; Boime I; Baird DT
Hum Reprod Update; 2009; 15(3):309-21. PubMed ID: 19182099
[TBL] [Abstract][Full Text] [Related]
20. Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response.
Brines M; Cerami A
J Intern Med; 2008 Nov; 264(5):405-32. PubMed ID: 19017170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
